Table 1.

Clinical trials of STIs in combination with endocrine therapy

Trial designTrial phaseDisease settingStatus
Phase II
    Sorafenib and AnastrozoleI/IIMetastaticOpen
    Trastuzumab + ExemestaneIIMetastaticCompleted
    Bevacizumab + LetrozoleIIMetastaticOpen
    Gefitinib ± TamoxifenII RCTMetastaticOpen
    Gefitinib + AnastrozoleII RCTMetastaticOpen
    Lapatinib + TamoxifenIIMetastatic second lineOpen
    Letrozole ± TipifarnibII RCTMetastaticCompleted
    Tipifarnib + FulvestrantIIMetastatic second lineOpen
    Tipifarnib + TamoxifenIIPost-tamoxifenTerminated
    Everolimus ± LetrozoleII RCTNeoadjuvantOpen
    Insulin-like growth factor receptor monoclonal antibody CP-751,871 + ExemestaneIIMetastaticPlanned
    Anastrozole ± GefitinibII RCTNeoadjuvantCompleted
Phase III
    Temsirolimus ± LetrozoleIIIMetastaticTerminated
    Lapatinib ± LetrozoleIIIMetastaticOpen
    Trastuzumab ± TamoxifenIIIMetastaticPlanned
    Letrozole ± EverolimusIIIMetastaticTerminated
    Letrozole ± EverolimusIIINeoadjuvantOpen